TABLE 3.
Overview and Diagnostic Accuracy Sorted by Type of Procedure
| SLNB | ||||||||||
| Author | Identification Rate | Sampling | SLNs, Median (range) | Ax-pCR %* | TP | FP | FN | TN | FNR % (CI) | NPV % (CI) |
| Alvarado | 92.7 | Tc and/or blue | 2 (1–7) | 35 | 57 | 0 | 15 | 39 | 21 (12–32) | 72 (58–84) |
| Boileau | 87.6 | Tc and/or blue | 2.7 (mean) | 35 | 76 | 0 | 7 | 44 | 8 (3–17) | 86 (74–94) |
| Boughey | 92.7 | Tc and/or blue | NR | 40.0 | 326 | 0 | 56 | 255 | 15 (11–19) | 82 (77–86) |
| Brown | NR | Tc and/or blue | 2 (1–10) | 30.2 | 47 | 0 | 13 | 26 | 22 (12–34) | 67 (50–81) |
| Carrera | 90.5 | Single radioactive | 2.2 (mean) (1–6) | 35.4 | 28 | 0 | 3 | 17 | 10 (2–26) | 85 (62–97) |
| Enokido | 90.9 | Tc and/or blue | 1.6 (mean) | 52 | 49 | 0 | 13 | 68 | 21 (12–33) | 84 (74–91) |
| Ge | 84.3 | Tc and/or blue | 2.4 (1–7) | 27.9 | 25 | 0 | 6 | 12 | 19 (7–37) | 67 (41–87) |
| Kang | 87.9 | Tc and/or blue | 2.8 (mean) (1–8) | 28.8 | 34 | 0 | 7 | 17 | 17 (7–32) | 71 (49–87) |
| Kuehn | 82.6 | Tc ± blue | NR | 48.8 | 51 | 0 | 12 | 60 | 19 (10–31) | 83 (73–91) |
| Ozmen | 92.2 | Tc + blue | 2.1 (1–5) | 28 | 44 | 0 | 7 | 20 | 14 (6–26) | 74 (54–89) |
| Park | 94.9 | Single, radioactive | 2,1 (mean) (1–12) | 40.8 | 78 | 0 | 22 | 69 | 22 (14–31) | 76 (66–84) |
| Pinero-Madrona | 84.0 | Tc ± blue | NR | 34.2 | 15 | 0 | 10 | 13 | 40 (21–61) | 57 (34–77) |
| Shen | 92.8 | Tc and/or blue | 2 (1–10) | 28.6 | 30 | 0 | 10 | 16 | 25 (13–41) | 62 (41–80) |
| Thomas | 86.7 | Single blue | 1,57 (mean) (1–4) | 31 | 15 | 0 | 3 | 8 | 17 (4–41) | 73 (39–94) |
| Yagata | 85.3 | Tc + blue | 2 (1–7) | 37 | 43 | 0 | 8 | 30 | 16 (7–29) | 79 (63–90) |
| Yu | 95.8 | Single: Blue | 1,48 (mean) (1–4) | 52.2 | 14 | 0 | 8 | 24 | 36 (17–59) | 75 (57–89) |
| Zetterlund | 77.9 | Tc and/or Blue | 2 (1–5) | 39.5 | 79 | 0 | 13 | 60 | 14 (8–23) | 82 (71–90) |
| ML | |||||||||||
| Author | IFR % | Pre-NST Marker | Post-NST Marker | N Lymph Nodes | Ax-pCR %* | TP | FP | FN | TN | FNR % (CI) | NPV % (CI) |
| Donker | 97 | Iodine seed | NA | 1 | 26 | 65 | 0 | 5 | 25 | 7 (2 – 16) | 83 (65–94) |
| Combination | |||||||||||||
| Author | IFR % | Sampling SLNB | Pre-NST Marker | Post-NST Marker | N Lymph Nodes | Ax-pCR %* | ML is SLN % | TP | FP | FN | TN | FNR% (CI) | NPV% (CI) |
| Caudle | 100% | Tc and/or blue | Clip | Iodine seed | NR | 41 | 77† | 49 | 0 | 1 | 35 | 2 (0–11) | 97 (85–1) |
| Siso | NR | Tc and/or blue | Clip | NA* | 3 median | 31.7 | 77 | 23 | 0 | 1 | 11 | 4 (0–21) | 92 (62–1) |
NA indicates not applicable; NR, not reported; Tc, technetium.
*Ax-pCR rate based on data of 2 × 2 contingency tables.
†Rate is based on 134 patients with a clipped node that underwent SLNB (it was documented if the clipped node was identified as an SLN). Eighty-five patients actually underwent TAD followed by cALND.